FDA says Elanco's Zenrelia promotional materials omit or misstate safety warnings and study results, misbranding the veterinary drug.
What happened
FDA reviewed Elanco's Zenrelia promotional communications, including two websites, a Product Brochure and Itch Tracker, a slide deck, and a Detailer. FDA found false or misleading claims and representations about safety and effectiveness, including omitted boxed-warning language and adverse-event data that differed from the approved prescribing information.
What FDA found
The websites, Product Brochure, and Itch Tracker left out “from modified live virus vaccines” in the boxed warning, hiding that the fatal vaccine risk involved a core vaccine.
FD&C Act sections 502(a), 502(n), and 201(n); 21 CFR 202.1(e)(5)Promotional materials replaced the specific 28-day-to-3-month pre-vaccination and 28-day post-vaccination withholding periods with a vague “for a time period before and after vaccination.”
FD&C Act sections 502(a), 502(n), and 201(n); 21 CFR 202.1(e)(5)The veterinarian website’s Safety section did not mention fatal vaccine-induced disease from modified live virus vaccines, inadequate vaccine response, or other prescribing-information warnings, and the information was not conspicuous.
FD&C Act section 201(n); 21 CFR 202.1(e)(5), (e)(7)(viii)The veterinarian website and “Reach for Zen” slide deck said the Vaccine Response Study dog had CAV-1 infection and signs before vaccination, conflicting with the prescribing information and FDA summary that concluded vaccine-induced disease secondary to Zenrelia immunosuppression.
FD&C Act sections 502(a), 502(n), and 201(n)The veterinarian website reported diarrhea and urinary tract infection rates that differed from the approved prescribing information, misrepresenting Zenrelia’s safety profile.
FD&C Act sections 502(a), 502(n), and 201(n)The Detailer prominently claimed 77% of Zenrelia-treated dogs returned to normal versus 53% of Apoquel-treated dogs based on a Day 112 secondary endpoint, despite a small disclaimer.
21 CFR 202.1(e)(7)(viii)
What FDA wants
Within 15 working days, submit a written response listing all Zenrelia promotional communications with such representations and explaining plans to discontinue them or cease distribution. If not completed, state why and when it will be done; if disputing, provide reasoning and support.
Who should pay attention
- veterinary drug sponsors and their promotional review teams
- animal-health regulatory affairs and advertising compliance staff
- veterinarians and dog owners who rely on promotional safety information
This is a summary. Read the original letter on fda.gov.